{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:32:05Z","timestamp":1787243525618,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jval.2024.11.012","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T15:59:25Z","timestamp":1734364765000},"page":"197-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prescription Medication Use and Expenditure for Atrial Fibrillation in the United States"],"prefix":"10.1016","volume":"28","author":[{"given":"Harshith","family":"Thyagaturu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Seetharam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Roma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Lacoste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Padala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Gonuguntla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Bilal","family":"Munir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshan","family":"Balla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jval.2024.11.012_bib1","first-page":"1056","article-title":"Comparing total medical expenditure between patients receiving direct oral anticoagulants vs warfarin for the treatment of atrial fibrillation: evidence from VA-Medicare dual enrollees","volume":"27","author":"Wong","year":"2021","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"2","key":"10.1016\/j.jval.2024.11.012_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","article-title":"Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence","volume":"114","author":"Miyasaka","year":"2006","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.jval.2024.11.012_bib3","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"issue":"9921","key":"10.1016\/j.jval.2024.11.012_bib4","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.jval.2024.11.012_bib5","article-title":"Effects of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease: a systematic review and meta-analysis","volume":"6","author":"Pan","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.jval.2024.11.012_bib6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.jval.2024.11.012_bib7","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJMoa2019422","article-title":"Early rhythm-control therapy in patients with atrial fibrillation","volume":"383","author":"Kirchhof","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.jval.2024.11.012_bib8","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.jacc.2022.03.337","article-title":"The increasing role of rhythm control in patients with atrial fibrillation: JACC state-of-the-art review","volume":"79","author":"Camm","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jval.2024.11.012_bib9","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ahj.2007.06.035","article-title":"Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation","volume":"154","author":"Allen LaPointe","year":"2007","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jval.2024.11.012_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ahj.2014.03.024","article-title":"Trends in the pharmacologic management of atrial fibrillation: data from the Veterans Affairs health system","volume":"168","author":"Vaughan-Sarrazin","year":"2014","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.jval.2024.11.012_bib11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s10840-022-01274-1","article-title":"Oral anticoagulant underutilization among elderly patients with atrial fibrillation: insights from the United States Medicare database","volume":"66","author":"Munir","year":"2023","journal-title":"J\u00a0Interv Card Electrophysiol"},{"issue":"22","key":"10.1016\/j.jval.2024.11.012_bib12","article-title":"Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020","volume":"11","author":"Navar","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.jval.2024.11.012_bib13","article-title":"Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics","volume":"14","author":"Abudureyimu","year":"2022","journal-title":"J\u00a0Mol Cell Biol"},{"key":"10.1016\/j.jval.2024.11.012_bib14","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1146\/annurev-publhealth-040617-013517","article-title":"Modeling health care expenditures and use","volume":"39","author":"Deb","year":"2018","journal-title":"Annu Rev Public Health"},{"issue":"7","key":"10.1016\/j.jval.2024.11.012_bib15","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1002\/cncr.34064","article-title":"Psychological distress and associated additional medical expenditures in adolescent and young adult cancer survivors","volume":"128","author":"Abdelhadi","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2024.11.012_bib16","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.amjcard.2024.07.027","article-title":"Health care expenditure in United States adults with heart failure with and without diabetes","volume":"228","author":"Shah","year":"2024","journal-title":"Am J Cardiol"},{"issue":"12","key":"10.1016\/j.jval.2024.11.012_bib17","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/eurjpc\/zwad140","article-title":"Obesity in heart failure with preserved ejection fraction with and without diabetes: risk factor or innocent bystander?","volume":"30","author":"Prausm\u00fcller","year":"2023","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.jval.2024.11.012_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12916-023-02764-3","article-title":"Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions","volume":"21","author":"Fauchier","year":"2023","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.jval.2024.11.012_bib19","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.42964","article-title":"Trends in use of oral anticoagulants in older adults with newly diagnosed atrial fibrillation, 2010-2020","volume":"5","author":"Ko","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jval.2024.11.012_bib20","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jval.2024.11.012_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.amjmed.2018.09.026","article-title":"Variation in the use of warfarin and direct oral anticoagulants in atrial fibrillation and associated cost implications","volume":"132","author":"Rodwin","year":"2019","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.jval.2024.11.012_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2175","article-title":"Association between use of warfarin for atrial fibrillation and outcomes among patients with end-stage renal disease: a systematic review and meta-analysis","volume":"3","author":"Randhawa","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.jval.2024.11.012_bib23","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11239-022-02727-0","article-title":"Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020","volume":"55","author":"Costa","year":"2023","journal-title":"J\u00a0Thromb Thrombolysis"},{"issue":"8","key":"10.1016\/j.jval.2024.11.012_bib24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jchf.2022.05.006","article-title":"Expenditure on heart failure in the United States: the Medical Expenditure Panel Survey 2009-2018","volume":"10","author":"Bhatnagar","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"9","key":"10.1016\/j.jval.2024.11.012_bib27","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1080\/03007995.2017.1345729","article-title":"Risk of stroke\/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or Rivaroxaban compared with warfarin in the United States Medicare population","volume":"33","author":"Amin","year":"2017","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"10.1016\/j.jval.2024.11.012_bib28","first-page":"1116","article-title":"Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the U.S. Department of Defense population","volume":"24","author":"Gupta","year":"2018","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.jval.2024.11.012_bib29","article-title":"Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care","volume":"362","author":"Vinogradova","year":"2018","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jval.2024.11.012_bib30","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/jce.13471","article-title":"Temporal trends of in-hospital complications associated with catheter ablation of atrial fibrillation in the United States: an update from Nationwide Inpatient Sample database (2011-2014)","volume":"29","author":"Tripathi","year":"2018","journal-title":"J\u00a0Cardiovasc Electrophysiol"},{"issue":"3","key":"10.1016\/j.jval.2024.11.012_bib31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.hroo.2022.12.005","article-title":"Contemporary trends in cardiac electrophysiology procedures in the United States, and impact of a global pandemic","volume":"4","author":"Scott","year":"2023","journal-title":"Heart Rhythm O2"},{"issue":"4","key":"10.1016\/j.jval.2024.11.012_bib32","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00228-023-03470-y","article-title":"Effect of digoxin on all-cause and cardiovascular mortality in patients with atrial fibrillation with and without heart failure: an umbrella review of systematic reviews and 12 meta-analyses","volume":"79","author":"Gazzaniga","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"issue":"35","key":"10.1016\/j.jval.2024.11.012_bib33","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029997","article-title":"Impact of social determinants of health on anticoagulant use among patients with atrial fibrillation: systemic review and meta-analysis","volume":"101","author":"Khatib","year":"2022","journal-title":"Med (Baltim)"},{"issue":"21","key":"10.1016\/j.jval.2024.11.012_bib34","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1161\/CIRCULATIONAHA.105.552984","article-title":"Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA)","volume":"112","author":"Stenestrand","year":"2005","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jval.2024.11.012_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001934","article-title":"Time trends in adherence to guideline recommendations for anticoagulation therapy in patients with atrial fibrillation and myocardial infarction","volume":"9","author":"Jortveit","year":"2022","journal-title":"Open Heart"},{"issue":"2","key":"10.1016\/j.jval.2024.11.012_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.annemergmed.2022.03.010","article-title":"Sex differences in the management of oral anticoagulation and outcomes for emergency department presentation of incident atrial fibrillation","volume":"80","author":"Islam","year":"2022","journal-title":"Ann Emerg Med"},{"issue":"7","key":"10.1016\/j.jval.2024.11.012_bib37","article-title":"Sex differences in the use of oral anticoagulants for atrial fibrillation: a report from the national cardiovascular data registry (NCDR\u00ae) PINNACLE registry","volume":"6","author":"Thompson","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.jval.2024.11.012_bib38","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/MLR.0b013e318195fa79","article-title":"Sensitivity of household reported medical conditions in the Medical Expenditure Panel Survey","volume":"47","author":"Machlin","year":"2009","journal-title":"Med Care"},{"key":"10.1016\/j.jval.2024.11.012_bib39","author":"Stagnitti"},{"issue":"1","key":"10.1016\/j.jval.2024.11.012_bib40","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12875-022-01961-y","article-title":"Real-world data in primary care: validation of diagnosis of atrial fibrillation in primary care electronic medical records and estimated prevalence among consulting patients\u2019","volume":"24","author":"de Burgos-Lunar","year":"2023","journal-title":"BMC Prim Care"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524067895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301524067895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T03:37:01Z","timestamp":1769917021000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301524067895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1098301524067895"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2024.11.012","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescription Medication Use and Expenditure for Atrial Fibrillation in the United States","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2024.11.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}